What is the recommended first-line therapy for status epilepticus?

First-Line Treatment for Status Epilepticus

Intravenous lorazepam 4 mg administered at 2 mg/min is the first-line treatment for status epilepticus, with demonstrated 65% efficacy in terminating seizures and superior effectiveness compared to diazepam. 1

Immediate Actions (0-5 Minutes)

• Administer IV lorazepam 4 mg at 2 mg/min immediately for any actively seizing patient—this achieves seizure cessation in approximately 65% of cases and is more effective than diazepam (59.1% vs 42.6% success rate). 1, 2

• Have airway equipment immediately available before administering any benzodiazepine, as respiratory depression can occur and may require intervention. 1, 2

• Check fingerstick glucose immediately and correct hypoglycemia while administering treatment, as this is a rapidly reversible cause. 2

• A second dose of lorazepam may be given after at least 1 minute if seizures persist, with a maximum of two total doses. 2

Alternative Routes When IV Access Is Unavailable

• Intramuscular midazolam 10 mg provides equivalent efficacy to IV lorazepam and is superior to IV lorazepam when IV access is not established (Level A evidence). 1, 2, 3

• Intranasal midazolam 0.2 mg/kg (maximum 6 mg) is an effective alternative, with onset of action within 1-2 minutes. 1, 2

• Rectal diazepam 0.5 mg/kg should be used if buccal/intranasal routes are not feasible—do NOT use intramuscular diazepam due to erratic absorption. 2

Definition and Timing

• Status epilepticus is defined as any seizure lasting ≥5 minutes or recurrent seizures without return to baseline consciousness—treatment should begin immediately at this threshold. 1, 2, 4, 5

• The operational definition was shortened from 30 minutes to 5 minutes because delayed treatment increases mortality from 5-22% to as high as 65% in refractory cases. 2

Second-Line Treatment (5-20 Minutes)

If seizures persist after adequate benzodiazepine dosing, immediately escalate to a second-line anticonvulsant without delay. 2

The 2019 ESETT trial demonstrated no significant difference in efficacy among levetiracetam, fosphenytoin, and valproate (seizure cessation rates 47%, 45%, and 46% respectively)—therefore, agent selection should prioritize safety profile and contraindications rather than efficacy alone. 2

Recommended Second-Line Agents (Ordered by Safety Profile)

Valproate is the preferred second-line agent based on superior safety:

• Valproate 20-30 mg/kg IV (maximum 3000 mg) over 5-20 minutes achieves 88% efficacy with 0% hypotension risk—the best safety profile of all second-line agents. 1, 2, 6

• Absolutely contraindicated in women of childbearing potential due to teratogenic risk. 2

Levetiracetam is the preferred alternative:

• Levetiracetam 30 mg/kg IV (maximum 2500-3000 mg) over 5 minutes achieves 68-73% efficacy with minimal cardiovascular effects (≈0.7% hypotension risk) and 20% intubation rate. 1, 2, 6

• No cardiac monitoring required, making it ideal for elderly patients or those with cardiovascular disease. 2

Fosphenytoin is the traditional option but has significant limitations:

• Fosphenytoin 20 mg PE/kg IV at maximum rate of 150 PE/min achieves 84% efficacy but carries 12% hypotension risk and 26.4% intubation rate. 1, 2

• Requires continuous ECG and blood pressure monitoring due to cardiovascular toxicity. 1, 2

• Fosphenytoin is preferred over phenytoin based on tolerability, but phenytoin is an acceptable alternative when fosphenytoin is unavailable. 2, 3

Phenobarbital is a reserve option:

• Phenobarbital 20 mg/kg IV over 10 minutes achieves 58.2% efficacy as initial second-line agent but carries higher risk of respiratory depression and hypotension. 1, 2, 6

Critical Concurrent Management

While administering anticonvulsants, simultaneously search for and treat reversible causes:

• Hypoglycemia—correct immediately with IV dextrose. 2

• Hyponatremia—the most common electrolyte disturbance precipitating seizures. 2

• Hypoxia—maintain airway and provide supplemental oxygen. 1, 6

• Drug toxicity or withdrawal (alcohol, benzodiazepines, barbiturates). 1, 2

• CNS infection—administer broad-spectrum antibiotics (vancomycin PLUS ceftriaxone or cefepime) if suspected. 6

• Acute stroke or intracerebral hemorrhage—especially in patients >40 years. 2

• Do NOT delay anticonvulsant administration to obtain neuroimaging—CT can be performed after seizure control is achieved. 2

Refractory Status Epilepticus (≥20 Minutes)

Refractory status epilepticus is defined as ongoing seizures despite adequate benzodiazepine therapy AND failure of one second-line anticonvulsant. 2, 6

Third-Line Anesthetic Agents

Midazolam infusion is the first-choice anesthetic agent:

• Loading dose: 0.15-0.20 mg/kg IV, followed by continuous infusion starting at 1 mg/kg/min (or 0.06 mg/kg/hour). 1, 2, 6

• Titrate by 1 mg/kg/min every 15 minutes up to maximum 5 mg/kg/min (0.3 mg/kg/hour). 1, 6

• Achieves 80% seizure control with 30% hypotension risk—superior safety profile compared to pentobarbital (77% hypotension). 1, 2, 6

Propofol is an alternative for intubated patients:

• Loading dose: 2 mg/kg IV, followed by infusion at 3-7 mg/kg/hour. 1, 2, 6

• Achieves 73% seizure control with 42% hypotension risk—requires mechanical ventilation but shorter duration than barbiturates (4 days vs 14 days). 1, 2

Pentobarbital has highest efficacy but worst safety profile:

• Loading dose: 13 mg/kg IV, followed by infusion at 2-3 mg/kg/hour. 1, 2

• Achieves 92% seizure control but 77% hypotension risk requiring vasopressors and mean 14 days mechanical ventilation. 1, 2

Essential Monitoring in Refractory Cases

• Continuous EEG monitoring is mandatory to guide anesthetic titration and detect ongoing electrical seizure activity—approximately 25% of patients have ongoing electrical seizures after clinical seizures stop. 1, 2, 6

• Continuous vital sign monitoring including blood pressure, oxygen saturation, and cardiac monitoring. 1, 6

• Transfer to ICU immediately for patients requiring third-line agents. 2

Common Pitfalls to Avoid

• Never use neuromuscular blockers alone (e.g., rocuronium)—they only mask motor manifestations while allowing continued electrical seizure activity and brain injury. 1

• Do not skip to third-line agents until benzodiazepines and a second-line agent have been tried. 1

• Do not attribute altered mental status solely to post-ictal state—obtain urgent EEG if patient does not awaken within expected timeframe, as nonconvulsive status epilepticus occurs in >50% of cases. 2

• Avoid delaying treatment for neuroimaging—stabilize the patient first, then image. 2

Prognosis

• Overall mortality for status epilepticus ranges from 5-22%, increasing dramatically to approximately 65% in refractory cases. 2

• The longer the duration of status epilepticus, the more difficult it is to terminate and the greater the risk of morbidity including neuronal injury, neurodisability, and de-novo epilepsy. 4, 7